+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Cancer Immunotherapy"

Antibody Drug Conjugate - Competitive Landscape, 2026 - Product Thumbnail Image

Antibody Drug Conjugate - Competitive Landscape, 2026

  • Report
  • April 2026
  • 280 Pages
  • Global
From
From
Checkpoint Inhibitors - Competitive Landscape, 2026 - Product Thumbnail Image

Checkpoint Inhibitors - Competitive Landscape, 2026

  • Report
  • January 2026
  • 180 Pages
  • Global
From
CTLA-4 Inhibitors - Competitive Landscape, 2026 - Product Thumbnail Image

CTLA-4 Inhibitors - Competitive Landscape, 2026

  • Report
  • January 2026
  • 220 Pages
  • Global
From
Oncolytic Virus - Competitive Landscape, 2026 - Product Thumbnail Image

Oncolytic Virus - Competitive Landscape, 2026

  • Report
  • January 2026
  • 250 Pages
  • Global
From
TIGIT Inhibitors - Competitive Landscape, 2026 - Product Thumbnail Image

TIGIT Inhibitors - Competitive Landscape, 2026

  • Report
  • January 2026
  • 100 Pages
  • Global
From
PD-1 and PD-L1 Inhibitors - Competitive Landscape, 2026 - Product Thumbnail Image

PD-1 and PD-L1 Inhibitors - Competitive Landscape, 2026

  • Report
  • January 2026
  • 400 Pages
  • Global
From
Biological Therapies for Cancer: Technologies and Global Markets - Product Thumbnail Image

Biological Therapies for Cancer: Technologies and Global Markets

  • Report
  • November 2025
  • 139 Pages
  • Global
From
Hepatic Tumor Pipeline Analysis Report 2025 - Product Thumbnail Image

Hepatic Tumor Pipeline Analysis Report 2025

  • Report
  • March 2026
  • 200 Pages
  • Global
From
From
Lupus Nephritis - Pipeline Insight, 2026 - Product Thumbnail Image

Lupus Nephritis - Pipeline Insight, 2026

  • Clinical Trials
  • May 2026
  • 180 Pages
  • Global
From
From
Bispecific Antibodies - Competitive Landscape, 2026 - Product Thumbnail Image

Bispecific Antibodies - Competitive Landscape, 2026

  • Report
  • January 2026
  • 450 Pages
  • Global
From
Monoclonal Antibodies - Competitive Landscape, 2026 - Product Thumbnail Image

Monoclonal Antibodies - Competitive Landscape, 2026

  • Report
  • January 2026
  • 450 Pages
  • Global
From
From
From
From
HER2 Positive Gastric Cancer Pipeline Analysis Report 2026 - Product Thumbnail Image

HER2 Positive Gastric Cancer Pipeline Analysis Report 2026

  • Report
  • May 2026
  • 150 Pages
  • Global
From
From
Loading Indicator

Cancer Immunotherapy is a type of Immune Disorders Drugs that uses the body's own immune system to fight cancer. It works by stimulating the body's natural defense system to recognize and attack cancer cells. This type of therapy is used to treat a variety of cancers, including melanoma, lymphoma, and leukemia. It can also be used to treat other types of cancer, such as breast, lung, and colorectal cancer. Cancer Immunotherapy is a rapidly growing field, with many new treatments being developed. It is an important part of the overall cancer treatment landscape, as it can provide a more targeted approach to treating cancer. It can also be used in combination with other treatments, such as chemotherapy and radiation therapy, to improve outcomes. Some of the companies in the Cancer Immunotherapy market include Merck, Bristol-Myers Squibb, AstraZeneca, Novartis, and Roche. These companies are developing a range of treatments, including monoclonal antibodies, vaccines, and cell-based therapies. Show Less Read more